Literature DB >> 12769509

Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women?

Benoit Bailey1.   

Abstract

OBJECTIVE: We reviewed evidence suggesting teratogenic risk associated with the use of antidotes in the acute management of poisoned pregnant women.
METHODS: Medline, Toxline, and DART/ETIC searches; references of retrieved articles, pertinent databases and textbooks were also searched.
RESULTS: There are case reports or case series of women who received antidotes for poisoning during (*) or after (+) the period of organogenesis who showed no fetal adverse effects. Some antidotes, however, have no teratogenic risk: atropine (cohort/surveillance studies)+, calcium (oral supplement: cohort study)+ and pyridoxine (Bendectin studies). Also, ethanol+, methylene blue (intra-amniotic injection but not oral) and penicillamine* can be considered teratogens but their risks in the treatment of poisonings are unknown. There is no epidemiologic study evaluating the risk of the following antidotes during pregnancy: N-acetylcysteine(*+), BAL (dimercaprol)+, black widow spider antivenin+, calcium EDTA+, crotalidae antivenin, crotalidae polyvalent immune FAB, cyanide antidote kit (amyl and sodium nitrate, sodium thiosulfate), deferoxamine(*+), digoxin immune FAB+, DMSA+, flumazenil+, fomepizole, methylene blue (IV), naloxone, physostigmine, pralidoxime+, protamine+; and parenteral pharmacologic doses of calcium+, folinic acid*, glucagon+, hydroxycobalamin, phytonadione (vitamin K), and pyridoxine.
CONCLUSIONS: Despite the limited evidence supporting the risk of antidote use during pregnancy, antidotes should be used when there is a clear maternal indication to decrease the morbidity or mortality associated with poisoning. The only exception may be penicillamine, which is a teratogen. Better antidotes exist for most poisonings that penicillamine could potentially treat. At this time, there is no known fetal indication for all antidotes. Reporting the use of an antidote during pregnancy should be encouraged, especially if used during the critical period of organogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12769509     DOI: 10.1002/bdra.10007

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  8 in total

Review 1.  [Fetomaternal pharmacology : anesthesiological approach in surgical interventions during pregnancy].

Authors:  M v Neindorff
Journal:  Anaesthesist       Date:  2010-05       Impact factor: 1.041

2.  [Poisonings in pregnancy].

Authors:  C Schaefer; P Hoffmann-Walbeck
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-02-16       Impact factor: 0.840

Review 3.  Risks versus benefits of gastrointestinal endoscopy during pregnancy.

Authors:  Mitchell S Cappell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-04       Impact factor: 46.802

4.  Acute Poisoning During Pregnancy: Observations from the Toxicology Investigators Consortium.

Authors:  Irene Zelner; Jeremy Matlow; Janine R Hutson; Paul Wax; Gideon Koren; Jeffrey Brent; Yaron Finkelstein
Journal:  J Med Toxicol       Date:  2015-09

Review 5.  Buprenorphine use in pregnant opioid users: a critical review.

Authors:  Michael Soyka
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

6.  Attempted suicide and pregnancy.

Authors:  Andrew E Czeizel
Journal:  J Inj Violence Res       Date:  2011-01

7.  [Acute organophosphorus intoxications in pregnant women].

Authors:  Mohamed Hafed Barhoumi; Badra Bannour; Tarek Barhoumi; Rami Jouini; Nadia Marwene; Mohamed Ridha Fatnassi
Journal:  Pan Afr Med J       Date:  2016-12-07

8.  Implementation of a Prenatal Naloxone Distribution Program to Decrease Maternal Mortality from Opioid Overdose.

Authors:  M Duska; D Goodman
Journal:  Matern Child Health J       Date:  2022-01-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.